← All trials
NCT06150560
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Jun 1, 2028
- Completion date
- Jun 1, 2028
- First posted
- Nov 29, 2023
- Last posted
- Nov 29, 2023
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mayo ClinicLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Mayo ClinicOverall official - principal investigator
- Mayo ClinicReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.